Clinical Trials Directory

Trials / Completed

CompletedNCT02929550

Impact of Guidelines on Cardiovascular and Economic Outcomes With Focus on Lipid Lowering Drugs

Predicted Impact on Cardiovascular and Economic Outcomes of Swedish Atherosclerotic Cardiovascular Disease Guideline 2014 With Focus on Lipid Lowering Treatment

Status
Completed
Phase
Study type
Observational
Enrollment
5,304 (actual)
Sponsor
Karolinska Institutet · Academic / Other
Sex
All
Age
74 Years
Healthy volunteers
Not accepted

Summary

Methods: All patients \<75 years registered in the Swedish Secondary Prevention after Heart Intensive care Admission registry (SEPHIA), will be followed-up within one year post-myocardia infarction (MI). The REACH risk prediction and a calibrated model for recurrent cardiovascular disease (CVD) events and death will be used to estimate base case, and calibrated CVD outcomes based on gender-specific risk factors. The predicted impact of the LDL-C reduction on the risk of CVD will be based on Cholesterol Treatment Trialists´ Collaboration findings.

Detailed description

SWEDEHEART is a Swedish national registry consisting of several sub registries in which patients with acute coronary syndrome are prospectively registered. Patient characteristics, hospital treatments, drug treatments at discharge, and outcome for patients consecutively included and treated at all Swedish coronary care units are collected in this registry.SEPHIA is a sub registry collecting data on secondary prevention and cardiac rehabilitation. Follow-up are registered at six to ten weeks and at 12 to14 months post MI by office visits or phone. Around 80 % of all Swedish acute myocardial infarction (AMI) patients below the age of 75 years are included in this register. In this study, a cohort of 5 904 (74% men) registered in the SEPHIA registry and who had one year follow-up during 2013, will be included. Data are aggregated and delivered from the SWEDEHEART/SEPHIA national registry. All patients were informed about their participation in the registry, the follow-up, and their right to decline participation. No written consent was obtained

Conditions

Interventions

TypeNameDescription
OTHERWell-controlledBoth groups got treatment but well-controlled reached target of LDL-C\<1.8 mmol/l

Timeline

Start date
2015-01-01
Primary completion
2016-01-01
Completion
2016-04-01
First posted
2016-10-11
Last updated
2020-11-25

Source: ClinicalTrials.gov record NCT02929550. Inclusion in this directory is not an endorsement.